ArticleCancer prevention research (Philadelphia, Pa.)2026
A Multiomic Liquid Biopsy for the Earlier Detection of Colorectal Cancer.
Article in Cancer prevention research (Philadelphia, Pa.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Navigating the molecular landscape: integrated multiomics liquid biopsy for biomarker discovery in early detection and monitoring of colorectal cancer.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes and limiting disease progression. Screening of average-risk individuals is essential for detecting tumors at an earlier, more treatable stage. However, adherence to current screening programs remains suboptimal. Liquid biopsies represent a promising alternative to stool-based tests and may play a key role in optimizing colorectal cancer detection and diagnostic pathways. In this study, 957 patients were recruited across various clinical sites in the United States: 48 with colorectal cancer, 157 with advanced precancerous lesions (APL), 331 with nonadvanced lesions, and 421 with a negative colonoscopy diagnosis. Blood was obtained from patients either prior to scheduled colonoscopy or before surgical resection and any anticancer therapies. Streck plasma samples were analyzed by the Dxcover Liquid Biopsy Platform and classified using machine learning algorithms. When colorectal cancer was classified against all other groups, the ROC curve generated an AUC value of 0.95, and test sensitivity and specificity were 90% and 89%, respectively. The diagnostic model accurately predicted 75% of stage I (3/4), 100% of stage II (15/15), 93% of stage III (14/15), and 100% of stage IV (6/6) colorectal cancers. For the advanced colorectal neoplasia model, 29% of APL were detected. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer. PREVENTION RELEVANCE: Timely diagnosis and intervention in colorectal cancer are critical to improving patient outcomes. A simple blood test with high sensitivity for early-stage colorectal cancer could significantly enhance patient outcomes. With continued development, this liquid biopsy has the potential to make a substantial impact on the early detection of colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.